Indication: Prostate Cancer
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Sub-indication: Metastatic Castrate-Resistant Prostate Cancer- Patients must have been previously treated with at least 1, but no more than 2 previous taxane regimens.
Line of Therapy: 2nd Line
Principal Investigator: Arash Rezazadeh, M.D.Norton Cancer Institute
Sponsor: Endocyte, Inc.
Email for more information: GU-NCIResearch@nortonhealthcare.org